CD3 Antibody Multispecific Binding for Tumor Cell Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective targeting and activation of T cells to specifically engage with tumor cells, particularly those expressing B7H3, a protein highly associated with various cancers, limiting their ability to induce significant tumor cell lysis.
Innovation Solution
Development of humanized antibodies or antigen-binding fragments specifically binding to human CD3, which can also target tumor-associated antigens like B7H3, enabling multispecific binding and activation of T cells to recognize and kill cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment is provided, but effective targeting and activation of T cells to specifically engage with tumor cells is lacking
Solution Approach 1:
The patent combines multiple functions into a single antibody molecule by creating a multispecific antibody that simultaneously binds to CD3 on T cells and tumor-associated antigens (such as B7H3) on tumor cells. This merging of targeting and activation functions into one molecule enables both specific tumor cell engagement and effective T cell activation, resolving the contradiction between reliability of T cell activation and adaptability of tumor cell targeting.
Solution Approach 2:
The multispecific antibody exhibits multi-functionality by performing multiple roles: it acts as a targeting agent to bind tumor cells via tumor-associated antigens, simultaneously serves as an activator by engaging CD3 on T cells, and functions as a bridge to form immunological synapses. This universal design allows a single therapeutic agent to address both the specificity and effectiveness limitations of current therapies.
2Productivity
If current therapies are used, then treatment is provided, but the ability to induce significant tumor cell lysis is limited
Solution Approach 1:
The multisspecific antibody performs preliminary action by pre-forming stable immunological synapses between T cells and tumor cells through simultaneous binding to CD3 and tumor-associated antigens. This pre-established connection ensures that when the antibody engages T cells, the tumor cell is already positioned for efficient lysis, thereby increasing tumor cell lysis efficiency while maintaining reliable T cell engagement.
Solution Approach 2:
The multispecific antibody acts as an intermediary molecule that mediates the interaction between T cells and tumor cells. By simultaneously binding to CD3 on T cells and tumor-associated antigens on tumor cells, the antibody serves as a bridge that facilitates direct contact and enhances the efficiency of tumor cell lysis while ensuring reliable T cell engagement, thus resolving the contradiction between productivity and reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively activate T cells to recognize and kill tumor cells expressing B7H3, demonstrating enhanced killing activity and therapeutic potential for various cancer types by specifically engaging with tumor-associated antigens.
Implementation Method 1
humanized antibodies or antigen-binding fragments specifically binding to human CD3
Implementation Method 2
The co-engagement of CD3 and tumor antigen(s) activates T cells, resulting in the lysis of tumor cells expressing tumor antigen(s)
Data Source
AI summary
The present disclosure relates to a CD3 antibody and a pharmaceutical use thereof. Specifically, the present disclosure relates to forming a multi-specificity antibody by using CD3 antibody and binding molecules of another target. The multi-specificity antibody may simultaneously bind to CD3 and another tumor-associated antigen, and bind and activate CD3-positive T cells while binding tumor-associated antigen-expressing cells, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. In addition, the present disclosure also provides a preparation and application of a multi-specific antibody.